BIM
ATRA icon

Bogle Investment Management’s Atara Biotherapeutics ATRA Stock Holding History

Bogle Investment Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-546
Closed -$567K – 354
2015
Q1 		$567K Buy
+546
New +$361K 0.04% 285

Other funds holding ATRA

Baupost Group
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bogle Investment Management's ATRA Position: Q2 2015 in Review

Bogle Investment Management sold out of Atara Biotherapeutics (ATRA) in Q2 2015, closing a stake of 546 shares — an estimated $567K sold.

Bogle Investment Management first reported a position in ATRA in Q1 2015 and held it in 1 quarter. The position peaked at $567K in Q1 2015. 74 funds tracked by Wall St. Rank hold ATRA as of Q2 2015.

  • Bogle Investment Management reported no remaining Atara Biotherapeutics position as of Q2 2015 after selling out during the quarter.
  • Bogle Investment Management sold 546 Atara Biotherapeutics shares in Q2 2015, an estimated $567K.
  • Bogle Investment Management first reported a position in Atara Biotherapeutics in Q1 2015 and held it in 1 quarter.
  • Bogle Investment Management's Atara Biotherapeutics position peaked at $567K in Q1 2015.
  • 74 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2015.

Based on Bogle Investment Management's 13F filing for Q2 2015, filed 13 Aug 2015.